

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data

Center: CRID:

Key Fields

Sequence Number: \_\_\_\_\_

Date Received: \_\_\_\_ - \_\_\_\_ - \_\_\_\_

CIBMTR Center Number: \_\_\_\_\_

CIBMTR Recipient ID: \_\_\_\_\_

Date of HCT for which this form is being completed: \_\_\_\_ - \_\_\_\_ - \_\_\_\_

HCT Type: (check all that apply)

- ☐ Autologous
- ☐ Allogeneic, unrelated
- ☐ Allogeneic, related

Product type: (check all that apply)

- ☐ Bone marrow
- ☐ PBSC
- ☐ Single cord blood unit
- ☐ Multiple cord blood units
- ☐ Other product

Specify: \_\_\_\_\_

Subsequent Transplant

Is this the report of a second or subsequent transplant for the same disease?

☐ yes ☐ no

Disease Assessment at Diagnosis

Questions: 1 - 22

1 Is this recipient a registered participant in the United States Immunodeficiency Network (USIDNET)?

☐ yes ☐ no

2 USIDNET ID: \_\_\_\_\_

3 What was the date of diagnosis? \_\_\_\_ - \_\_\_\_ - \_\_\_\_

4 Is there a family history of hemophagocytic disorders?

☐ yes ☐ no ☐ Unknown

Specify affected member(s):

5 Aunt(s)

☐ yes ☐ no

6 Uncle(s)

☐ yes ☐ no

7 Cousin(s)

☐ yes ☐ no

8 Sibling(s)

☐ yes ☐ no

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data

Center: CRID:

9 Other family member(s)

yes no

10 Specify relationship: \_\_\_\_\_

11 Is there a family history of consanguinity (inter-familial marriage / descent from common ancestors)?

yes no Unknown

12 Was genetic testing used to confirm the diagnosis?

yes no Unknown

Specify genetic mutation(s) identified:

13 FHL 2 / Perforin deficiency (PRF1)

Yes No Unknown Not done

14 FHL 3 / MUNC 13-4 (UNC13D)

Yes No Unknown Not done

15 FHL 4 / Syntaxin 11 (STX11)

Yes No Unknown Not done

16 FHL 5 / Munc 18-2 (STXBP2)

Yes No Unknown Not done

17 IL2-inducible T-cell kinase (ITK)

Yes No Unknown Not done

18 Other mutation

Yes No Unknown Not done

19 Specify other mutation: \_\_\_\_\_

20 Were central nervous system (CNS) abnormalities found on computed tomography (CT or CAT) or magnetic resonance imaging (MRI) scans?

yes no Unknown

21 Date scan was performed: \_\_\_\_ - \_\_\_\_ - \_\_\_\_

22 Was documentation submitted to the CIBMTR?

(e.g. CT or MRI scan report)

yes no

Clinical Features and Laboratory Studies at Diagnosis

Questions: 23 - 47

23 Anemia

(Hgb < 9 g/dL)

yes no Unknown

24 Degranulation assay of NK cells

(as defined by local laboratory)

Normal Abnormal Unknown

25 Fevers

(>38.5° C or > 101.3° F for >7 days within 1 week of diagnosis)

yes no Unknown

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data

Center: CRID:

26 Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

yes no Unknown

27 Serum ferritin

Known Unknown

28 \_\_\_\_\_ ng/mL(µg/L)

29 Triglycerides

Known Unknown

30 \_\_\_\_\_ mg/dL mmol/L

31 Fibrinogen antigen assay (factor I; fibrinogen activity; functional fibrinogen; fibrinogen antigen)

Known Unknown

32 \_\_\_\_\_ g/dL mg/dL µmol/L g/L

33 NK cell function

Absent (≤10% lower limit of normal)  
Decreased (11-50% lower limit of normal)  
Normal  
Unknown

34 Neutropenia (ANC < 1.0 x 10<sup>9</sup> /L)

yes no Unknown

35 Soluble interleukin-2 receptor alpha chain (sCD25)

(as defined by local laboratory)

Normal Elevated Unknown

36 Splenomegaly (spleen palpable > 3 cm below left costal margin)

yes no Unknown

37 Thrombocytopenia (platelets < 100 x 10<sup>9</sup> /L)

yes no Unknown

Specify the cerebrospinal fluid findings at diagnosis

38 Neopterin level

Normal Elevated Not done

39 Protein

Normal Elevated Not done

40 WBC count

Normal (≤ 5 cells/µL)  
Elevated (> 5 cells/µL)  
Not done

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data

Center: CRID:

Specify the site(s) where hemophagocytosis was documented at diagnosis:

41 Bone marrow

☐ yes ☐ no

42 Cerebrospinal fluid (CSF)

☐ yes ☐ no

43 Liver

☐ yes ☐ no

44 Lymph nodes

☐ yes ☐ no

45 Spleen

☐ yes ☐ no

46 Other site

☐ yes ☐ no

47 Specify other site: \_\_\_\_\_

Disease Assessment Between Diagnosis and the Start of the Preparative Regimen (Conditioning)

Questions: 48 - 58

48 Were central nervous system (CNS) abnormalities found on computed tomography (CT or CAT) or magnetic resonance imaging (MRI) scans?

☐ yes ☐ no ☐ Unknown

49 Date scan was performed: \_\_\_\_ - \_\_\_\_ - \_\_\_\_

50 Were there any clinical neurologic abnormalities present?

☐ yes ☐ no ☐ Unknown

Specify neurologic abnormalities:

51 Abnormal gait

☐ yes ☐ no

52 Cranial nerve palsies

☐ yes ☐ no

53 Developmental delay

☐ yes ☐ no

54 Motor weakness

☐ yes ☐ no

55 Seizures

☐ yes ☐ no

56 Sensory deficits

☐ yes ☐ no

57 Other neurologic abnormality

☐ yes ☐ no

58 Specify other neurologic abnormality: \_\_\_\_\_

History of Infection at Any Time Prior to the Preparative Regimen (Conditioning)

Questions: 59 - 74

Specify documented infection(s) associated with HLH:

59 Was an infection documented?

yes no

Specify infection(s):

60 Cytomegalovirus (CMV)

yes no

61 Specify the test method used for diagnosis of CMV  
(check only one)

Antigen

Polymerase chain reaction (PCR)

Shell vial test

62 Epstein-Barr virus (EBV)

yes no

Specify results used for diagnosis of EBV infection:

63 In situ hybridization

Positive Negative Not Done

64 Polymerase chain reaction (PCR)

Positive Negative Not Done

65 Serology

Positive Negative Not Done

Specify titers:

66 EBNA

Positive Negative

67 Early antigen

Positive Negative

68 Viral capsid IgG

Positive Negative

69 Viral capsid IgM

Positive Negative

70 Was documentation submitted to the CIBMTR?

yes no

71 Other infection

yes no

Other Infection (1)

Questions: 72 - 74

72 Specify other infection

# Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data

Center:

CRID:

73 If other organism, specify: \_\_\_\_\_

74 Site

\_\_\_\_\_

## Pre-HCT Therapy

Questions: 75 - 107

75 Was therapy given?

☐ yes ☐ no

## Line of Therapy (1)

Questions: 76 - 107

### Line of Therapy

76 Specify the purpose of therapy

☐ Induction

☐ Maintenance

☐ Treatment for disease relapse / reactivation

77 Date therapy started

☐ Known ☐ Unknown

78 Date started: \_\_\_\_ - \_\_\_\_ - \_\_\_\_

79 Alemtuzumab (Campath)

☐ yes ☐ no

80 Specify total dose given: \_\_\_\_\_ mg

81 Antithymocyte globulin (ATG)

☐ yes ☐ no

82 Corticosteroids

(intrathecal) (e.g., IT-A-Hydrocort)

☐ yes ☐ no

83 Corticosteroids

(systemic) (e.g., Dexamethasone)

☐ yes ☐ no

84 Cyclosporine (CSA, Neoral, Sandimmune)

☐ yes ☐ no

85 Etoposide (VP-16, VePesid)

☐ yes ☐ no

86 Intrathecal methotrexate (IT MTX)

☐ yes ☐ no

87 IVIG

☐ yes ☐ no

# Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data

Center:

CRID:

**88** Teniposide (VM26)

☐ yes ☐ no

**89** Other therapy

☐ yes ☐ no

**90** Specify other therapy: \_\_\_\_\_

**91** Was this therapy given following the HLH-94 / HLH 2004 protocol of the Histiocyte Society?

☐ yes ☐ no ☐ Unknown

**Specify response to therapy:**

**92** Was CNS disease inactive?

☐ yes ☐ no ☐ Unknown

**93** Normal or stable CT or MRI of CNS

☐ yes ☐ no ☐ Unknown

**94** Neopterin level

☐ Normal ☐ Elevated ☐ Not done

**95** Protein

☐ Normal ☐ Elevated ☐ Not done

**96** WBC count

☐ Normal ( $\leq 5$  cells/ $\mu$ L)

☐ Elevated ( $> 5$  cells/ $\mu$ L)

☐ Not done

**97** Was systemic disease inactive?

☐ yes ☐ no ☐ Unknown

**98** ANC  $> 1.0 \times 10^9$  /L (without growth factor support)

☐ yes ☐ no ☐ Unknown

**99** Hemoglobin  $\geq 9$  g/dL without transfusion

☐ yes ☐ no ☐ Unknown

**100** Hepatomegaly resolved ( $\leq 3$ cm below costal margin)

☐ yes ☐ no ☐ Unknown

**101** Normal fibrinogen

☐ yes ☐ no ☐ Unknown

**102** Normal triglycerides

☐ yes ☐ no ☐ Unknown

**103** Platelets  $> 100 \times 10^9$  /L without transfusion

☐ yes ☐ no ☐ Unknown

Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data

Center: CRID:

104 Splenomegaly resolved ( ≤3 cm below costal margin)

yes no Unknown

105 Were there any signs of disease relapse / reactivation?

yes no

106 Specify the date of the relapse / reactivation: - - - - - - - - - -

107 Specify the site of the relapse / reactivation

CNS Systemic CNS and systemic

Clinical Features and Laboratory Studies Prior to the Preparative Regimen (Conditioning)

Questions: 108 - 127

108 Anemia

(Hgb < 9 g/dL)

yes no Unknown

109 Degranulation assay of NK cells

(as defined by local laboratory)

Normal Abnormal Unknown

110 Fevers

(>38.5° C or > 101.3° F for > 7 days)

yes no Unknown

111 Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

yes no Unknown

112 Serum ferritin

Known Unknown

113 ng/mL(µg/L)

114 Triglycerides

Known Unknown

115 mg/dL mmol/L

116 Fibrinogen antigen assay (factor I; fibrinogen activity; functional fibrinogen; fibrinogen antigen)

Known Unknown

117 g/dL mg/dL µmol/L g/L

118 NK cell function

Absent (≤10% lower limit of normal)

Decreased (11-50% lower limit of normal)

Normal

Unknown



Form 2039 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Pre-HCT Data

Center: CRID:

119 Neutropenia (ANC < 1.0 x 10<sup>9</sup> /L)

☐ yes ☐ no ☐ Unknown

120 Soluble interleukin-2 receptor alpha chain (sCD25)  
(as defined by local laboratory)

☐ Normal ☐ Elevated ☐ Unknown

121 Splenomegaly (spleen palpable > 3 cm below left costal margin)

☐ yes ☐ no ☐ Unknown

122 Thrombocytopenia (platelets < 100 x 10<sup>9</sup> /L)

☐ yes ☐ no ☐ Unknown

Specify the cerebrospinal fluid findings at last assessment prior to the start of the preparative regimen

123 Neopterin level

☐ Normal ☐ Elevated ☐ Not done

124 Protein

☐ Normal ☐ Elevated ☐ Not done

125 WBC count

☐ Normal (≤ 5 cells/μL)

☐ Elevated (> 5 cells/μL)

☐ Not done

126 Were central nervous system (CNS) abnormalities found on computed tomography (CT or CAT) or magnetic resonance imaging (MRI) scans?

☐ yes ☐ no ☐ Unknown

127 Date scan was performed: \_\_\_\_ - \_\_\_\_ - \_\_\_\_

First Name: \_\_\_\_\_

Last Name: \_\_\_\_\_

E-mail address: \_\_\_\_\_

Date: \_\_\_\_ - \_\_\_\_ - \_\_\_\_